



Antifungal Combinations in Fungal Infections

Guest Editors:

Dr. Patrick Schwarz

1. Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg, Germany
2. Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg, Germany

patrick.schwarz@med.uni-marburg.de

Dr. Eric Dannaoui

1. Unité de Parasitologie-Mycologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, F-75015 Paris, France
2. Faculté de Médecine, Université Paris Descartes, F-75006 Paris, France

eric.dannaoui@aphp.fr

Deadline for manuscript submissions:

31 July 2021

Message from the Guest Editors

Dear Colleagues,

Many fungal infections are difficult to treat. Antifungal combinations are an interesting tool, not only to overcome this resistance, but also because of the potential synergism obtained, when drugs are acting together. Various methods of assessing antifungal combinations have been used. In vitro, most often used is the checkerboard method based on the EUCAST or CLSI microdilution broth reference techniques. The gold standard for assessing antifungal combinations in vivo are survival models in mammals, but fungal burden studies have also been used successfully, and alternative minihost models have been implemented. In view of the fact that drug repurposing has major advantages like the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines, combinations of antifungals with non-antifungal drugs have also become attractive. In this Special Issue several reviews will address the current status of antifungal combinations against fungi of medical importance. Original works are also welcome.

Dr. Patrick Schwarz

Dr. Eric Dannaoui

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David S. Perlin

Hackensack Meridian Health
Center for Discovery and
Innovation, 340 Kingsland Street,
Nutley, NJ 07110, USA

Message from the Editor-in-Chief

The *Journal of Fungi* (JoF, ISSN 2309-608X) is an international, peer-reviewed, scientific, open access journal that provides an advanced forum for studies related to pathogenic fungi, fungal biology, and all other aspects of fungal research. Research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access:—free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: Indexed in the Science Citation Index Expanded (SCIE - Web of Science), BIOSIS Previews, Chemical Abstracts / SciFinder (ACS), as well as Scopus. Citations available in PubMed, full-text archived in PubMed Central.

Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.8 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2020).

Contact Us
